Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH)

Barré, Tangui; Rojas, Teresa Rojas; Lacombe, Karine; Protopopescu, Camélia; Poizot‐Martin, Isabelle; Nishimwe, Marie Libérée; Zucman, David; Esterle, Laure; Billaud, Éric; Aumaître, Hugues; Bouchaud, Olivier; Rey, David; Piroth, Lionel; Salmon‐Céron, Dominique; Wittkop, Linda; Sogni, Philippe; Carrieri, Patrizia; Serfaty, Lawrence; Marcellin, Fabienne

doi:10.1080/14787210.2021.1884545

Cited by 7 publications

(7 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a longitudinal evaluation on 703 HCV–HIV-coinfected individuals, Carrieri et al showed that cannabis use was associated with a lower insulin-resistance risk [ 97 ]. Similar findings were observed in a five-year longitudinal study, with regular or daily cannabis use that was associated with an over 50% lower risk of elevated steatosis (fatty liver index) in 997 HCV–HIV-coinfected individuals [ 92 ], and with a reduced risk of diabetes [ 94 ]. Nordmann et al also showed similar findings in a cross-sectional study of 838 HCV–HIV-coinfected participants, with a reduced prevalence of steatosis independently associated with daily cannabis use [ 95 ].…”

Section: Impact Of Cannabis Intake and Cannabinoid-based Medicine On ...supporting

confidence: 73%

“…Another study showed that daily compared with nondaily cannabis use was significantly associated with moderate to severe fibrosis in a cohort of 204 untreated chronically HCV-infected participants [ 103 ]. In contrast, more recent studies have consistently documented a significant reduced risk of insulin resistance, liver steatosis, inflammation, fibrosis, and cirrhosis in HCV-infected individuals who smoked cannabis compared to noncannabis users [ 90 , 92 , 93 , 94 , 95 , 96 , 97 , 104 , 105 ]. In a longitudinal evaluation on 703 HCV–HIV-coinfected individuals, Carrieri et al showed that cannabis use was associated with a lower insulin-resistance risk [ 97 ].…”

Section: Impact Of Cannabis Intake and Cannabinoid-based Medicine On ...mentioning

confidence: 99%

See 1 more Smart Citation

Cannabinoids and Chronic Liver Diseases

Bouassa

Sebastiani

Marzo

et al. 2022

IJMS

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD), alcohol-induced liver disease (ALD), and viral hepatitis are the main causes of morbidity and mortality related to chronic liver diseases (CLDs) worldwide. New therapeutic approaches to prevent or reverse these liver disorders are thus emerging. Although their etiologies differ, these CLDs all have in common a significant dysregulation of liver metabolism that is closely linked to the perturbation of the hepatic endocannabinoid system (eCBS) and inflammatory pathways. Therefore, targeting the hepatic eCBS might have promising therapeutic potential to overcome CLDs. Experimental models of CLDs and observational studies in humans suggest that cannabis and its derivatives may exert hepatoprotective effects against CLDs through diverse pathways. However, these promising therapeutic benefits are not yet fully validated, as the few completed clinical trials on phytocannabinoids, which are thought to hold the most promising therapeutic potential (cannabidiol or tetrahydrocannabivarin), remained inconclusive. Therefore, expanding research on less studied phytocannabinoids and their derivatives, with a focus on their mode of action on liver metabolism, might provide promising advances in the development of new and original therapeutics for the management of CLDs, such as NAFLD, ALD, or even hepatitis C-induced liver disorders.

show abstract

Section: Impact Of Cannabis Intake and Cannabinoid-based Medicine On ...supporting

confidence: 73%

Section: Impact Of Cannabis Intake and Cannabinoid-based Medicine On ...mentioning

confidence: 99%

Cannabinoids and Chronic Liver Diseases

Bouassa

Sebastiani

Marzo

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Further investigations should be carried out to test whether the seemingly beneficial effect of cannabis use on BMI in HBV-infected patients also translates into metabolic or hepatic benefits. Moreover, as the ECS influences gastrointestinal homeostasis, direct effects of cannabis use (and/or its derivatives) on hepatic diseases should also be investigated further 45 , especially as similar effects have already been suggested by studies conducted in HIV-HCV co-infected patients 17,29,46,47 . The potential protective effect of cannabis and cannabinoids on hepatic steatosis 27,[47][48][49] is of particular interest for HBVinfected patients, as hepatic steatosis is a strong predictor of cancer and mortality in this population 50 .…”

Section: Discussionmentioning

confidence: 94%

Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort)

Barré

Pol

Ramier

et al. 2022

Cannabis and Cannabinoid Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cannabis and/or cannabis compounds may also have a direct beneficial effect on these problems. More specifically, a growing body of research, including observational, preclinical, and clinical data, suggests that phytocannabinoids may play a role in the prevention or treatment of hepatic steatosis (Berk et al 2021 ; Barré et al 2021b ). As modulators of the endocannabinoid system, which is a main therapeutic target for treating diabetes mellitus (Veilleux et al 2019 ), cannabis compounds may exert a beneficial role on the development of diabetes in different populations (Bielawiec et al 2020 ; Wargent et al 2013 ; Jadoon et al 2016 ; Meah et al 2021 ), including HCV-infected people (Barré et al 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

et al. 2022

View full text Add to dashboard Cite

Background Patients with chronic hepatitis C virus (HCV) infection are at greater risk of developing metabolic disorders. Obesity is a major risk factor for these disorders, and therefore, managing body weight is crucial. Cannabis use, which is common in these patients, has been associated with lower corpulence in various populations. However, this relationship has not yet been studied in persons with chronic HCV infection. Methods Using baseline data from the French ANRS CO22 Hepather cohort, we used binary logistic and multinomial logistic regression models to test for an inverse relationship between cannabis use (former/current) and (i) central obesity (i.e., large waist circumference) and (ii) overweight and obesity (i.e., elevated body mass index (BMI)) in patients from the cohort who had chronic HCV infection. We also tested for relationships between cannabis use and both waist circumference and BMI as continuous variables, using linear regression models. Results Among the 6348 participants in the study population, 55% had central obesity, 13.7% had obesity according to their BMI, and 12.4% were current cannabis users. After multivariable adjustment, current cannabis use was associated with lower risk of central obesity (adjusted odds ratio, aOR [95% confidence interval, CI]: 0.45 [0.37–0.55]), BMI-based obesity (adjusted relative risk ratio (aRRR) [95% CI]: 0.27 [0.19–0.39]), and overweight (aRRR [95% CI]: 0.47 [0.38–0.59]). This was also true for former use, but to a lesser extent. Former and current cannabis use were inversely associated with waist circumference and BMI. Conclusions We found that former and, to a greater extent, current cannabis use were consistently associated with smaller waist circumference, lower BMI, and lower risks of overweight, obesity, and central obesity in patients with chronic HCV infection. Longitudinal studies are needed to confirm these relationships and to assess the effect of cannabis use on corpulence and liver outcomes after HCV cure. Trial registration ClinicalTrials.gov identifier: NCT01953458.

show abstract

Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH)

Cited by 7 publications

References 60 publications

Cannabinoids and Chronic Liver Diseases

Cannabinoids and Chronic Liver Diseases

Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort)

Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

Contact Info

Product

Resources

About